PADCEV
Analogs of PADCEV
Find cheaper analogs and generic equivalents for PADCEV.
Active Ingredient: ENFORTUMAB VEDOTIN
Product Overview
About PADCEV
PADCEV (enfortumab vedotin) is a prescription medicine used to treat adults with locally advanced or metastatic urothelial cancer who have previously received chemotherapy, including a platinum-containing chemotherapy, or have disease progression during or following a platinum-containing chemotherapy.
Key Benefits & Uses
- Treatment of adults with locally advanced or metastatic urothelial cancer who have previously received chemotherapy, including a platinum-containing chemotherapy, or have disease progression during or following a platinum-containing chemotherapy.
- Administered by intravenous infusion every 3 weeks.
- May be used in combination with other medications to treat urothelial cancer.
Active Ingredient & Action
ENFORTUMAB VEDOTIN is a monoclonal antibody-drug conjugate (mAb-ADC) that targets nectin-4, a protein highly expressed in urothelial cancer cells. Upon binding to nectin-4, ENFORTUMAB VEDOTIN is internalized and releases the microtubule inhibitor monomethyl auristatin E (MMAE), which inhibits cell division and induces apoptosis in cancer cells.
Important Notes
Before receiving PADCEV, inform your doctor about all your medical conditions, including kidney or liver disease. PADCEV may cause severe side effects, including peripheral neuropathy, fatigue, and nausea. Your doctor will monitor your condition and adjust your treatment as needed. It is essential to follow your doctor's instructions and attend regular follow-up appointments to ensure the safe and effective use of PADCEV.
Visitor ratings
Help others by rating how useful this product page is.
No ratings yet — be the first.